Anna G. Turkina

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I/II study.

Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I/II study.

Journal: Haematologica

Published: November 13, 2025

Violence against female sex workers in the state of Piauí, Brazil - a cross-sectional study.

Violence against female sex workers in the state of Piauí, Brazil - a cross-sectional study.

Journal: Scientific reports

Published: July 18, 2025

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Journal: Leukemia

Published: May 29, 2025

Allele-Specific PCR for Detection of Missense Mutations in the Chimeric BCR::ABL1 Gene Causing Failure of Tyrosine Kinase Inhibitor Therapy in CML Patients.

Allele-Specific PCR for Detection of Missense Mutations in the Chimeric BCR::ABL1 Gene Causing Failure of Tyrosine Kinase Inhibitor Therapy in CML Patients.

Journal: International journal of molecular sciences

Published: March 17, 2025

Radio-morphologic assessment of dental formation leading to permanent teeth and third molar age estimation models.

Radio-morphologic assessment of dental formation leading to permanent teeth and third molar age estimation models.

Journal: Morphologie : bulletin de l'Association des anatomistes

Published: March 07, 2025

Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.

Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.

Journal: Blood advances

Published: February 03, 2025

Sequencing and ranking patterns of morphological dental features radiographically assessed for human identification.

Sequencing and ranking patterns of morphological dental features radiographically assessed for human identification.

Journal: Legal medicine (Tokyo, Japan)

Published: December 27, 2024

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.

Journal: JAMA oncology

Published: November 21, 2024

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Journal: Annals of hematology

Published: October 27, 2024

Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.

Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.

Journal: Leukemia

Published: September 17, 2024

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study.

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study.

Journal: Journal of hematology & oncology

Published: August 29, 2024

Morphological Evaluation and Immunohistochemical Analysis of the Reparative Potential of the Buccal Fat Pad.

Morphological Evaluation and Immunohistochemical Analysis of the Reparative Potential of the Buccal Fat Pad.

Journal: Medicina (Kaunas, Lithuania)

Published: March 01, 2024

Showing 1-12 of 61

Last Updated: 09/26/2026